Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, et al. Marfan syndrome. Nat Rev Dis Prim. 2021;7:64.
Chiu HH, Wu MH, Chen HC, Kao FY, Huang SK. Epidemiological profile of Marfan syndrome in a general population: a national database study. Mayo Clin Proc. 2014;89:34–42.
Groth KA, Hove H, Kyhl K, Folkestad L, Gaustadnes M, Vejlstrup N, et al. Prevalence, incidence, and age at diagnosis in Marfan syndrome rare systemic diseases. Orphanet J Rare Dis. 2015;10:1–10.
Dietz HC, Cutting CR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337–9.
Article CAS PubMed Google Scholar
Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De BJ, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47:476–85.
Article CAS PubMed Google Scholar
Arnaud P, Milleron O, Hanna N, Ropers J, Ould Ouali N, Affoune A, et al. Clinical relevance of genotype–phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet Med. 2021;23:1296–304.
Article CAS PubMed PubMed Central Google Scholar
Murdoch JL, Walker BA, Halpern BL, Kuzma JW, Mckusick VA. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med. 1972;286:804–8.
Article CAS PubMed Google Scholar
Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75:157–60.
Article CAS PubMed Google Scholar
Gray J, Bridges A, West R, McLeish L, Stuart A, Dean J, et al. Life expectancy in British Marfan syndrome populations. Clin Genet. 1998;54:124–8.
Article CAS PubMed Google Scholar
Shores J. Progression of aortic dilatation and the benefit of long-term beta adrenergic blockade in Marfan’s syndrome. N Engl J Med. 1994;330:1335–41.
Article CAS PubMed Google Scholar
Groenink M, Den Hartog AW, Franken R, Radonic T, De Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34:3491–500.
Article CAS PubMed Google Scholar
Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014;371:2061–71.
Article PubMed PubMed Central Google Scholar
Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015;36:2160–6.
Forteza A, Evangelista A, Sánchez V, Teixidó-Turà G, Sanz P, Gutiérrez L, et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur Heart J. 2016;37:978–85.
Article CAS PubMed Google Scholar
Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet. 2019;394:2263–70.
Article CAS PubMed PubMed Central Google Scholar
Byers PH. Determination of the molecular basis of Marfan syndrome: a growth industry. J Clin Invest. 2004;114:161–3.
Article CAS PubMed PubMed Central Google Scholar
Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–21.
Article CAS PubMed PubMed Central Google Scholar
Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022;400:822–31.
Article CAS PubMed PubMed Central Google Scholar
Yagyu T, Noguchi T, Asano Y, Ida K, Ogata S, Nishimura K, et al. Association between genetic diagnosis and clinical outcomes in patients with heritable thoracic aortic disease. J Am Heart Assoc. 2023;12: e028625.
Article PubMed PubMed Central Google Scholar
Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36:855–60.
Article CAS PubMed PubMed Central Google Scholar
Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–81.
Article CAS PubMed Google Scholar
Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788–98.
Article CAS PubMed Google Scholar
Attias D, Stheneur C, Roy C, Collod-Béroud G, Detaint D, Faivre L, et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation. 2009;120:2541–9.
Article CAS PubMed Google Scholar
van de Laar IM, Oldenburg RA, Pals G, Roos-hesselink JW, de Graaf BM, Verhagen JM, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011;43:121–8.
Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-bober J, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet. 2012;44:922–7.
Article CAS PubMed PubMed Central Google Scholar
Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012;44:916–21.
Article CAS PubMed PubMed Central Google Scholar
Rienhoff HY, Yeo CY, Morissette R, Khrebtukova I, Melnick J, Luo S, et al. A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys–Dietz syndrome. Am J Med Genet Part A. 2013;161:2040–6.
van der Linde D, van de Laar IM, Bertoli-Avella AM, Oldenburg RA, Bekkers JA, Mattace-Raso FU, et al. Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol. 2012;60:397–403.
MacCarrick G, Black JH, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, Guerrerio AL, et al. Loeys–Dietz syndrome: a primer for diagnosis and management. Genet Med. 2014;16:576–87.
Article PubMed PubMed Central Google Scholar
Teixidó-tura G, Franken R, Galuppo V, García-moreno LG, Borregan M, Mulder BJM, et al. Heterogeneity of aortic disease severity in patients with Loeys–Dietz syndrome. Heart. 2016;102:626–32.
Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, et al. International registry of patients carrying TGFBR1 or TGFBR2 mutations results of the MAC (Montalcino aortic consortium). Circ Cardiovasc Genet. 2016;9:548–58.
Article CAS PubMed PubMed Central Google Scholar
Isselbacher EM, Preventza O, Hamilton Black J, Augoustides JG, Beck AW, Bolen MA, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease. J Am Coll Cardiol. 2022;80:e223–393.
Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175C:8–26.
Pepin M, Schwarze U, Superti-Furga A, Byers P. Clinical and genetic features of Ehlers–Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673–80.
Article CAS PubMed Google Scholar
Frank M, Albuisson J, Ranque B, Golmard L, Mazzella J-MM, Bal-Theoleyre L, et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers–Danlos syndrome. Eur J Hum Genet. 2015;23:1657–64.
Article CAS PubMed PubMed Central Google Scholar
Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical validity of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol. 2018;72:605–15.
Comments (0)